Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.27 - $47.80
Previous CloseN/A
Volume41.45K
Average Volume (3M)450.64K
Market Cap
$2.83B
Enterprise Value$2.42B
Total Cash (Recent Filing)$67.75M
Total Debt (Recent Filing)$15.01M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 13, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.01
Shares Outstanding76,542,810
10 Day Avg. Volume527,165
30 Day Avg. Volume450,645
Standard Deviation0.17
R-Squared0.13
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.47
Enterprise Value/Ebitda-9.59
Forecast
1Y Price Target
$54.70Price Target Upside47.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Xenon News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAnalysts remain optimistic for success in the ongoing Ph. III program, and for uptake across patients in the refractory FOS and PGTCS landscape.
Bears Say
Financial PerformanceThe increase in research and development spending, along with other expenses, has led to a reduction in the price target for Xenon Pharmaceuticals from $55 to $50.
Management ChangesXENE shares are under pressure most likely due to news of the CFO departing.
---
Ownership Overview
0.16% Insiders
30.50% Mutual Funds
62.23% Other Institutional Investors
5.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $33.27 and its highest was $47.80 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $2.83B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is May 13, 2025 which is in 70 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Feb 27, 2025. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.861 by $0.021.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -0.92.
How many shares outstanding does Xenon have?
Xenon has 76,542,810 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.861. Following the earnings report the stock price went down -3.367%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
---
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.70 (47.76% Upside)
$54.70 (47.76% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 234.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $770.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.61%
12-Months-Change
Fundamentals
Return on Equity
-27.85%
Trailing 12-Months
Asset Growth
10.60%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
---
XENE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall. Xenon Pharmaceuticals demonstrated significant progress in its clinical development programs, including plans to expand azetukalner into new indications such as bipolar depression. The company is also in a strong financial position to support its pipeline and strategic goals. However, challenges in enrolling patients for the PGTC study and the announced departure of CFO Sherry Aulin were noted.Read More>---
XENE Stock 12 Month Forecast
Average Price Target
$54.70
▲(47.76% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering XENE
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+34.28%
assigned a buy rating 3 months ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +34.28% per trade.
---